News and Announcements
Article highlight
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Published 24.04.26
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Capital Insights
1
Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain
Read more
2
From Mediocre Portfolios to 18% Returns: EFM’s Radical Transparency in Private Markets
Read more
3
Silent Pain and Smart Monitors: The High-Stakes Race to De-Risk the Operating Theatre
Read more
4
The $3 Billion Blind Spot: How Venstra Medical is using “Collapsible” Physics to Challenge a Global Med-Tech Giant
Read more
Executive Interviews
Capital Insights
Company Updates
Venture Investor Interviews
Backed By Leading Investment Groups and Family Offices
